

- Office of Population Affairs
  - Office of Adolescent Health—Teen Pregnancy Prevention Program Under Part C, section C–G, Organization, revise to include that the Office of Population Affairs will manage the Office of Adolescent Health (OAH) and the activities managed by OAH. Section C–G will incorporate the current reference to section C–R:

The Office of Adolescent Health is headed by a Director who reports to the Assistant Secretary for Health.

Under Section C–G. Functions, retitle all references to the Office of Adolescent Health (ACR) under Part C, Section C–R, to the Office of Population Affairs (ACG).

Under Section C–R. Delete all other organizational references to the Office of Adolescent Health (AGR).

*II. Delegations of Authority:* All delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegation, if allowed, provided they are consistent with this reorganization.

(Authority: 44 U.S.C. 3101)

**Alex M. Azar II,**  
Secretary.

[FR Doc. 2019–07124 Filed 4–10–19; 4:15 pm]

**BILLING CODE 4150–34–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Statement of Organization, Functions, and Delegations of Authority

**AGENCY:** Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion, HHS.

**ACTION:** Notice.

**SUMMARY:** The Office of the Assistant Secretary for Health, Office of Disease Prevention and Health Promotion organization has modified its organizational structure.

**DATES:** This new organizational structure was approved by the Secretary of Health and Human Services and takes effect on April 6, 2019.

**FOR FURTHER INFORMATION CONTACT:** Tara Broido, Acting Director, Office of Communications, Office of the Assistant Secretary for Health, 200 Independence Ave. SW, Room 715–G, Washington, DC 20201 Phone 202.690.7694.

**SUPPLEMENTARY INFORMATION:** Part A (Office of the Secretary, U.S. Department of Health and Human Services) of the Statement of Organization, Functions, and Delegations of Authority of the

Department of Health and Human Services (60 FR 27804, dated October 31, 1995, and corrected at 75 FR 53304, August 31, 2010, and amended most recently at 82 FR 3005, dated January 5, 2017) is amended to reflect the reorganization of the Office of Disease Prevention and Health Promotion (ODPHP) to merge the President's Council on Sports, Fitness and Nutrition (PCSFN), Office of the Assistant Secretary for Health (OASH) activities to be managed under the Office of Disease Prevention and Health Promotion. This reorganization is being undertaken to create a more effective structure that better reflects the two offices' missions and streamlines the office's operations.

Under Part C, Section C–L, add the current reference: The Office of Disease Prevention and Health Promotion (ODPHP) is headed by the Director, will comprise of the following: The Office of Disease Prevention and Health Promotion and the Office of the President's Council on Sports, Fitness, and Nutrition (PCSFN). The ODPHP will be responsible for managing the activities of ODPHP and will manage the PCSFN, to be headed by the Executive Director of the PCSFN. The Executive Director of PCSFN will be a Senior Advisor to ODPHP and report to the Deputy Assistant Secretary for Health for Operations.

- Office of Disease Prevention and Health Promotion
  - Office of the President's Council on Sports, Fitness, and Nutrition

Under Part C, Section C–E, Organization and Function, make the following changes:

- Retitle all references to the function of the Office of the President's Council on Sports, Fitness, and Nutrition (ACE) to the Office of the President's Council on Sports, Fitness, and Nutrition (ACL).

- Delete all references to the organizational structure of the Office of the President's Council on Sports, Fitness, and Nutrition (ACE) and replace with: The Office of the President's Council on Sports, Fitness, and Nutrition (ACL) is headed by the Executive Director of the PCSFN. The Executive Director of PCSFN will be a Senior Advisor to ODPHP and report to the Deputy Assistant Secretary for Health for Operations.

*II. Delegations of Authority:* All delegations and re-delegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegation, if allowed, provided they are consistent with this reorganization.

(Authority: 44 U.S.C. 3101)

**Alex M. Azar II,**  
Secretary.

[FR Doc. 2019–07125 Filed 4–10–19; 4:15 pm]

**BILLING CODE 4150–32–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; Complications of Hemolysis and Transfusion Therapy.

*Date:* May 7, 2019.

*Time:* 8:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.  
*Contact Person:* Melissa E. Nagelin, Ph.D., Scientific Review Officer, Office of Scientific Review, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7202, Bethesda, MD 20892, 301–827–7951, [nagelinmh2@nhlbi.nih.gov](mailto:nagelinmh2@nhlbi.nih.gov).

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; MESA Field Centers.

*Date:* May 20, 2019.

*Time:* 8:00 a.m. to 9:00 a.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* Crowne Plaza Washington National Airport, 1489 Jefferson Davis Hwy., Arlington, VA 22202.

*Contact Person:* William J. Johnson, Ph.D., Scientific Review Officer, Office of Scientific Review, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7178, Bethesda, MD 20892–7924, 301–827–7938, [johnsonw@nhlbi.nih.gov](mailto:johnsonw@nhlbi.nih.gov).

*Name of Committee:* National Heart, Lung, and Blood Institute Special Emphasis Panel; MESA Coordinating Center.

*Date:* May 20, 2019.

*Time:* 9:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate contract proposals.

Place: Crowne Plaza Washington National Airport, 1480 Crystal Drive, Arlington, VA 22202.

Contact Person: William J. Johnson, Ph.D., Scientific Review Officer, Office of Scientific Review, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7178, Bethesda, MD 20892-7924, 301-827-7938, [johnsonw@nhlbi.nih.gov](mailto:johnsonw@nhlbi.nih.gov).

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Mechanisms of Blood Pressure Regulation Program Project Grant Review.

Date: May 23, 2019.

Time: 1:00 p.m. to 3:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Shelley S. Sehnert, Ph.D., Scientific Review Officer, Office of Scientific Review, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7206, Bethesda, MD 20892-7924, 301-435-0303, [ssehnert@nhlbi.nih.gov](mailto:ssehnert@nhlbi.nih.gov).

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; NHLBI Short-Term Experience in Research.

Date: May 29, 2019.

Time: 11:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

Contact Person: Giuseppe Pintucci, Ph.D., Scientific Review Officer, Office of Scientific Review, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7192, Bethesda, MD 20892, 301-827-7969, [Pintuccig@nhlbi.nih.gov](mailto:Pintuccig@nhlbi.nih.gov).

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; NHLBI Institutional Training Grants.

Date: May 30, 2019.

Time: 12:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Giuseppe Pintucci, Ph.D., Scientific Review Officer, Office of Scientific Review, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Room 7192, Bethesda, MD 20892, 301-827-7969, [Pintuccig@nhlbi.nih.gov](mailto:Pintuccig@nhlbi.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: April 8, 2019.

Ronald J. Livingston, Jr.,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019-07250 Filed 4-11-19; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Interagency Coordinating Committee on the Validation of Alternative Methods; Notice of Public Meeting; Request for Public Input

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

**SUMMARY:** The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) will hold a public forum to share information and facilitate direct communication of ideas and suggestions from stakeholders. Interested persons may attend in person or view the meeting remotely by webcast. Time will be set aside for questions and public statements on the topics discussed. Registration is requested for both public attendance and oral statements, and required for remote access. Information about the meeting and registration are available at <http://ntp.niehs.nih.gov/go/iccvamforum-2019>.

**DATES:** Meeting: May 23, 2019, 9:00 a.m. to approximately 4:00 p.m. Eastern Daylight Time (EDT).

**Registration for Onsite Meeting:** Deadline is May 10, 2019.

**Registration for Webcast:** Deadline is May 23, 2019.

**Submission of Oral Public Statements:** Deadline is May 10, 2019.

**ADDRESSES:** Meeting Location: William H. Natcher Conference Center, National Institutes of Health, Bethesda, MD 20892.

**Meeting web page:** The preliminary agenda, registration, and other meeting materials are at <http://ntp.niehs.nih.gov/go/iccvamforum-2019>.

**FOR FURTHER INFORMATION CONTACT:** Dr. Warren Casey, Director, National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM); email: [warren.casey@nih.gov](mailto:warren.casey@nih.gov); telephone: (984) 287-3118.

#### SUPPLEMENTARY INFORMATION:

**Background:** ICCVAM, a congressionally mandated committee, promotes the development and validation of alternative testing strategies that protect human health and

the environment while replacing, reducing, or refining animal use.

ICCVAM's goals include promotion of national and international partnerships between governmental and nongovernmental groups, including academia, industry, advocacy groups, and other key stakeholders. To foster these partnerships ICCVAM initiated annual public forums in 2014 to share information and facilitate direct communication of ideas and suggestions from stakeholders (79 FR 25136).

This year's meeting will be held on May 23, 2019, at the National Institutes of Health (NIH) in Bethesda, MD. The meeting will include presentations by NICEATM and ICCVAM members on current activities related to the development and validation of alternative test methods and approaches, including activities relevant to implementation of the strategic roadmap for establishing new approaches to evaluate the safety of chemicals and medical products in the United States (83 FR 7487).

Following each presentation, there will be an opportunity for participants to ask questions of the ICCVAM members. Instructions for submitting questions will be provided to remote participants prior to the webcast. The agenda will also include time for participants to make public oral statements relevant to the ICCVAM mission and current activities.

**Preliminary Agenda and Other Meeting Information:** The preliminary agenda, list of discussion topics, background materials, ICCVAM roster, and public statements submitted prior to the meeting will be posted by May 17 at <http://ntp.niehs.nih.gov/go/iccvamforum-2019>. Interested individuals are encouraged to visit this web page to stay abreast of the most current meeting information.

**Meeting and Registration:** This meeting is open to the public with time scheduled for questions and oral public statements following presentations from ICCVAM and NICEATM. The public may attend the meeting at NIH, where attendance is limited only by the space available, or view remotely by webcast. Those planning to attend the meeting in person are encouraged to register at <http://ntp.niehs.nih.gov/go/iccvamforum-2019> by May 10, 2019, to facilitate planning for appropriate meeting space. Those planning to view the webcast must register at <http://ntp.niehs.nih.gov/go/iccvamforum-2019>; registration will be available through May 23, 2019. The URL for the webcast will be provided in the email confirming registration.